126120-87-4

Basic information

• Product Name: 2,2-DIFLUORO-BENZO[1,3]DIOXOLE-4-BORONIC ACID
• Synonyms: 2,2-DIFLUORO-BENZO[1,3]DIOXOLE-4-BORONIC ACID;2,2-Difluorobenzo[1,3]dioxole-4-voronic acid;3-Borono-1,2-(difluoromethylenedioxy)benzene;2,2-Difluorobenzo[d][1,3]dioxole-4-ylboronic acid;2,2-Difluoro-1,3-benzodio...;(2,2-Difluorobenzo[d][1,3]dioxol-4-yl)boronic acid;2,2-Difluoro-1,3-benzodioxole-4-boronic acid 98%;2,3-(Difluoromethylenedioxy)benzeneboronic acid, 4-Borono-2,2-difluoro-1,3-benzodioxole
• CAS NO: 126120-87-4
• Molecular Formula: C₇H₅BF₂O₄
• Molecular Weight: 201.92
• Mol File: 126120-87-4.mol

Chemical Properties

• Boiling Point: 299°C at 760 mmHg
• Flash Point: 134.6°C
• Appearance: /
• Density: 1.58g/cm³
• Vapor Pressure: 0.000549mmHg at 25°C
• Refractive Index: 1.533
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 7.80±0.40(Predicted)
• CAS DataBase Reference: 2,2-DIFLUORO-BENZO[1,3]DIOXOLE-4-BORONIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 2,2-DIFLUORO-BENZO[1,3]DIOXOLE-4-BORONIC ACID(126120-87-4)
• EPA Substance Registry System: 2,2-DIFLUORO-BENZO[1,3]DIOXOLE-4-BORONIC ACID(126120-87-4)

Safety Data

• Hazard Codes: Xi
• Hazardous Substances Data: 126120-87-4(Hazardous Substances Data)

Usage

Uses

2,2-Difluorobenzo[1,3]dioxole-4-boronic acid

InChI:InChI=1/C7H5BF2O4/c9-7(10)13-5-3-1-2-4(8(11)12)6(5)14-7/h1-3,11-12H

Upstream product

• 1583-59-1 2,2-difluoro-1,3-benzodioxole 
• 121-43-7 Trimethyl borate 
• 110-18-9 N,N,N,N,-tetramethylethylenediamine 
• 144584-66-7 4-bromo-2,2-difluoro-1,3-benzodioxole 
• 7732-18-5 water 

Downstream Products

• 1190058-32-2 N-(7-(2,2-difluorobenzo[d][1,3]dioxol-4-yl)pyrazolo[1,5-a]pyrimidin-5-yl)-4-(2-hydroxypropan-2-yl)benzamide 
• 1112662-77-7 C₂₁H₁₃BrF₂N₂O₄S 
• 1613711-10-6 N-(tert-butyl)-3-(3-(2,2-difluorobenzo[d][1,3]dioxol-4-yl)-1H-pyrrolo[2,3-b]pyridin-5-yl)-N-methylbenzenesulfonamide 
• 1613712-83-6 C₃₀H₂₅F₂N₃O₅S₂ 
• 1613712-84-7 C₂₈H₂₂F₂N₄O₅S₂ 
• 1613712-85-8 C₃₂H₂₉F₂N₃O₆S₂ 
• 1613712-86-9 C₃₀H₂₅F₂N₃O₄S₂ 
• 1613712-87-0 C₃₁H₂₇F₂N₃O₄S₂ 
• 1613712-88-1 C₂₈H₂₂F₂N₄O₅S₂ 
• 875639-20-6 3-(2,2-difluorobenzo[d][1,3]dioxol-4-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-tosyl-1H-pyrrolo[2,3-b]pyridine 
• 1613713-01-1 C₃₄H₃₃F₂N₅O₆S 
• 1092476-50-0 (+/-)-N'-[3,5-bis(trifluoromethyl)phenyl]-2-(2,2-difluoro-1,3-benzodioxol-4-yl)-2-(4-methyl-1-piperazinyl)acetohydrazide 
• 131341-86-1 Fludioxonil 

Relevant articles and documents

Synthesis of Pyrroles via Consecutive 6π-Electrocyclization/Ring-Contraction of Sulfilimines

We present a modular, synthetic entry to polysubstituted pyrroles employing readily available 2,5-dihydrothiophenes. Ring-opening of the heterocycle provides access to a panel of 1,3-dienes which undergo pyrrole formation in the presence of inexpensive chloramine-T trihydrate. The transformation is conducted in an open flask and proceeds at ambient temperatures (23 °C) in nondry solvents. A careful adjustment of the electronics and sterics of the 1,3-diene precursor allows for the isolation of key intermediates. DFT studies identified a reaction mechanism that features a 6π-electrocyclization of a sulfilimine intermediate followed by spontaneous ring-contraction to reveal the pyrrole skeleton.

CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF

Small molecule calpain modulator compounds, including their pharmaceutically acceptable salts, can be included in pharmaceutical compositions. The compounds can be useful in inhibiting calpain, or competitive binding with calpastatin, by contacting them with CAPN1, CAPN2, and/or CAPN9 enzymes residing inside a subject. The compounds and composition can also be administered to a subject in order to treat a fibrotic disease or a secondary disease state or condition of a fibrotic disease.

NOVEL COMPOUNDS

The invention provides compounds of formula (I): Said compounds being modulators of Kv3 channels and of use in the prophylaxis or treatment of related disorders.

HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS

The invention provides compounds of formula (I): Said compounds being inhibitors of Kv3 channels and of use in the prophylaxis or treatment of related disorders.

HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS

The invention provides compounds of formula (I): Said compounds being modulators of Kv3 channels and of use in the prophylaxis or treatment of related disorders.

HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS

The invention provides compounds of formula (I): Said compounds being inhibitors of Kv3 channels and of use in the prophylaxis or treatment of related disorders.

N-PHENYL HYDRAZIDES AS MODULATORS OF THE GHRELIN RECEPTOR

The present invention relates to novel compounds of formula (I) or a pharmaceutically acceptable salt or solvate thereof, wherein: each R1 is independently selected from the group consisting of Cl, Br, CH3 and CF3; X is carbon or nitrogen; R1a is H or a straight C1-3 alkyl group; R2a is H or a methyl group R2 is selected from the group consisting of C1-3alkyl, H and -(CH2)n-, wherein n is 3 or 4 and the terminal carbon of the chain is bonded to the carbon atom adjacent to the nitrogen bearing the R2 group, such that a fused 6,5 or 6,6-bicyclic ring is formed. Y is selected from the group consisting of: phenyl which may be unsubstituted or substituted by one or more substituents independently selected from the group consisting of C1-3alkyl, C1-3alkoxy, halogen, C1-3alkyl substituted by 1 to 7 fluoro atoms and C1-3alkoxy substituted by 1 to 7 fluoro atoms; pyridyl which may be unsubstituted or substituted by one or more substituents independently selected from the group consisting of C1-3alkyl, OCH3, CF3, CN, and halogen; naphthyl which may be unsubstituted or substituted by one or more substituents independently selected from the group consisting of F and OCH3; pyrimidinyl; imidazo[1,2-a]pyridine-6-yl; benzothiophen-2-yl; benzothiophen-5-yl; benzofuran-2-yl; dibenzo[b,d]furan-3-yl; dibenzo[b,d]thiophen-2-yl; dibenzo[b,d]thiophen-4-yl; 1,3- benzodioxol-5-yl; 2,3-dihydro-1,4-benzodioxin-5-yl; 2,3-dihydro-1,4-benzodioxin-6-yl; 2,3- dihydro-1-benzofuran-4-yl; 2,2-difluoro-1,3-benzodiox-4-yl; pyridazinyl; imidazolyl; oxazolyl; pyrazolyl; thiazolyl; and triazolyl; with the proviso that when Y is 2,3-dihydro-1,4-benzodioxin-6-yl, R1 is not Cl; processes for their preparation, intermediates useble in these processes, pharmaceutical compositions containing them and their use in therapy, for example as modulators of of the growth hormone secretagogue receptor (also referred to as the ghrelin receptor or GHSR1a receptor) and/or for the treatment and/or prophylaxis of a disorder mediated by the ghrelin receptor.

Herbicidal benzodioxoles and benzodioxanes

Compounds of Formula I, and their N-oxides and agriculturally-suitable salts, are disclosed which are useful for controlling undesired vegetation STR1 wherein: STR2 T is O or S; W is a single bond, O, S or NR6 ; X is N or CH; Y is N or CH; Z is